UBS initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $30 price target The firm believes Summit’s lead program, ivonescimab, could become the new standard of care in front-line non-small cell lung cancer with a greater than $7B peak sales opportunity, or $11B unadjusted, while the stock is pricing in about $5B, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Revolution Medicines, Summit Therapeutics enter clinical collaboration
- Revolution Medicines, Summit Therapeutics team to evaluate RAS inhibitors
- Summit Therapeutics’ Promising Clinical Trials and Market Potential Drive Buy Rating
- Summit Therapeutics Signs Sublease with Ascendis Pharma
- Summit Therapeutics Holds Successful 2025 Annual Meeting